Click to watch the webinar video clip
Click to watch the webinar video clip
Generating biologically relevant cell models is often the slowest and most critical step in the drug discovery process. For targeted protein degradation (TPD) and other small-molecule programs, real-time quantification of endogenous protein levels can provide decisive insights; however, conventional antibody assays and overexpression systems can add weeks to timelines.
Join Promega and EditCo to discover a streamlined path from CRISPR edit to actionable data. You’ll see how a single 11-amino-acid HiBiT tag, precisely inserted by EditCo and verified by deep NGS, converts your protein of interest into a bright Nano-Glo® biosensor with >6-log linear dynamic range. Then learn how Promega’s ready-made assays and high- throughput screening services translate that signal into degrader potency curves and kinetic profiles—often within days of receiving your cells.
In this session, you’ll learn:
- HiBiT fundamentals: why a tag this small delivers such a big, quantitative signal.
- Editing at speed: how EditCo ships HiBiT knock-in pools or clones—NGS-verified and assay-ready—in as little as 10 weeks.
- Assay to insight: leveraging Promega’s platforms to profile degrader efficacy, kinetics, and selectivity.
- Beyond TPD: extending the same models to pathway modulation, target validation, and ortholog studies across your discovery pipeline.
Cut months off discovery timelines and illuminate your next breakthrough—faster than ever. (Co-sponsored by Promega Corporation and EditCo Bio)
Fill out the form below to watch the webinar!
